drying and irritating issues related to prescription acne products.
Important features of OTC products used for acne patients
include: non-irritating, well-tolerated, anti-inflammatory, repairs
skin barrier, addresses hyperchromia post-acne, follicular
occlusion, sebum regulatory, and pleasant texture.
CONCLUSION
Advisors reported using several different products as mono-, adjunctive, and maintenance therapy in acne. The panels' recommendations were similar to those given in the practical treatment algorithm on acne for Latin American countries, Spain and Portugal.
OTC monotherapy is used for mild acne, and OTC adjunctive therapy is mainly applied for moderate acne in combination with prescription treatment.
Reasons for using OTC maintenance therapy are antiinflammatory action, prevention of acne flares, oil control, and minimization of scars.
Common ingredients in acne products (eg, BPO and retinoids) are effective but may cause skin irritation and impair the skin barrier function. Ceramides containing skincare may offer acne patients benefits to help restore skin barrier function.
OTC monotherapy is used for mild acne, and OTC adjunctive therapy is mainly applied for moderate acne in combination with prescription treatment.
Reasons for using OTC maintenance therapy are antiinflammatory action, prevention of acne flares, oil control, and minimization of scars.
Common ingredients in acne products (eg, BPO and retinoids) are effective but may cause skin irritation and impair the skin barrier function. Ceramides containing skincare may offer acne patients benefits to help restore skin barrier function.
DISCLOSURES
The authors disclosed receipt of an unrestricted educational grant from CeraVe International for support with this work's research.
All authors contributed to the development, writing, and reviewing the article and agree with its content.
All authors contributed to the development, writing, and reviewing the article and agree with its content.
REFERENCES
1. Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168(3):474-485.
2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease study 2010. Lancet. 2012;380:2163-2196.
3. Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172(Suppl 1):3-12.
4. Rocha MA, Bagatin E. Adult-onset acne: prevalence, impact, and management challenges. Clin Cosmet Investig Dermatol. 2018;11:59-69.
5. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527-1534.
6. Kaminsky A, Florez-White M, Bagatin E, Arias MI. Large prospective study on adult acne in Latin America and the Iberian Peninsula: risk factors, demographics, and clinical characteristics. Int J Dermatol. 2019 Nov;58(11):1277-1282. doi: 10.1111/ijd.14441. Epub 2019 March 18. PMID: 30883707
7. Bagatin E, Florez-White M, Bagatin E, Arias-Gomez MI, Kaminsky A. Algorithm for acne treatment: Ibero-Latin American consensus. An. Bras. Dermatol. 2017;92 (5) 1-10. https://doi.org/10.1590/abd1806-4841.20177003
8. Gollnick HPM. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol. 2015;29(Suppl. 5):1-7.
9. Acne. Un enfoque global. Kaminsky A, Florez-White M. 2ª.ed. Buenos Aires: Alfaomega Grupo Editor; Colegio Ibero Latinoamericano de Dermatología. 2012.
10. Florez-White M. Procedimientos cosméticos complementários. In: Kaminsky A, Florez M. Acné, un enfoque global. 3rd ed. e-book. Buenos Aires: CILAD 2015;16, 225-230.
11. Araviiskaia E, Dreno B. The role of dermocosmetics in acne vulgaris. J Eur Acad Dermatol Venereol. 2016; 30, 926–935.
12. Dreno B, Araviiskaia E, Kerob D, Andriessen A, Anifilova M, Fabbrocini G. Nonprescription acne vulgaris treatments: Their role in our treatment armamentarium—An international panel discussion. J Cosmet Dermatol. 2020;19(9):2201-2211. DOI: 10.1111/jocd.13497
13. Lynde CW, Andriessen A, Barankin B, et al. Moisturizers and ceramidecontaining moisturizers may offer concomitant therapy with benefits. J Clin Aesthet Dermatol. 2014;7(3):18-26.
14. Thiboutot D, Del Rosso JQ. Acne vulgaris and the epidermal barrier: Is acne vulgaris associated with inherent epidermal abnormalities that cause impairment of barrier functions? Do any topical acne therapies alter the structural and/or functional integrity of the epidermal barrier? J Clin Aesthet Dermatol. 2013;6(2):18-24.
15. Zeichner JA. Inflammatory acne treatment: review of current and new topical therapeutic options. J Drugs Dermatol. 2016;15(1 Suppl 1):s11-s16.
16. Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74:945-73.e33.
17. Hsu P, Litman GI, Brodell RT. Overview of the treatment of acne vulgaris with topical retinoids. Postgrad Med. 2011;123:153-61.
18. Kaplan YC, Ozsarfati J, Etwel F, Nickel C, Nulman I, Koren G. Pregnancy outcomes following first-trimester exposure to topical retinoids: a systematic review and meta-analysis. Br J Dermatol. 2015;173:1132-41.
19. Del Rosso JQ. Clinical relevance of skin barrier changes associated with the use of oral isotretinoin: the importance of barrier repair therapy in patient management. J Drugs Dermatol. 2013;12(6):626-31.
2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease study 2010. Lancet. 2012;380:2163-2196.
3. Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172(Suppl 1):3-12.
4. Rocha MA, Bagatin E. Adult-onset acne: prevalence, impact, and management challenges. Clin Cosmet Investig Dermatol. 2018;11:59-69.
5. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527-1534.
6. Kaminsky A, Florez-White M, Bagatin E, Arias MI. Large prospective study on adult acne in Latin America and the Iberian Peninsula: risk factors, demographics, and clinical characteristics. Int J Dermatol. 2019 Nov;58(11):1277-1282. doi: 10.1111/ijd.14441. Epub 2019 March 18. PMID: 30883707
7. Bagatin E, Florez-White M, Bagatin E, Arias-Gomez MI, Kaminsky A. Algorithm for acne treatment: Ibero-Latin American consensus. An. Bras. Dermatol. 2017;92 (5) 1-10. https://doi.org/10.1590/abd1806-4841.20177003
8. Gollnick HPM. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol. 2015;29(Suppl. 5):1-7.
9. Acne. Un enfoque global. Kaminsky A, Florez-White M. 2ª.ed. Buenos Aires: Alfaomega Grupo Editor; Colegio Ibero Latinoamericano de Dermatología. 2012.
10. Florez-White M. Procedimientos cosméticos complementários. In: Kaminsky A, Florez M. Acné, un enfoque global. 3rd ed. e-book. Buenos Aires: CILAD 2015;16, 225-230.
11. Araviiskaia E, Dreno B. The role of dermocosmetics in acne vulgaris. J Eur Acad Dermatol Venereol. 2016; 30, 926–935.
12. Dreno B, Araviiskaia E, Kerob D, Andriessen A, Anifilova M, Fabbrocini G. Nonprescription acne vulgaris treatments: Their role in our treatment armamentarium—An international panel discussion. J Cosmet Dermatol. 2020;19(9):2201-2211. DOI: 10.1111/jocd.13497
13. Lynde CW, Andriessen A, Barankin B, et al. Moisturizers and ceramidecontaining moisturizers may offer concomitant therapy with benefits. J Clin Aesthet Dermatol. 2014;7(3):18-26.
14. Thiboutot D, Del Rosso JQ. Acne vulgaris and the epidermal barrier: Is acne vulgaris associated with inherent epidermal abnormalities that cause impairment of barrier functions? Do any topical acne therapies alter the structural and/or functional integrity of the epidermal barrier? J Clin Aesthet Dermatol. 2013;6(2):18-24.
15. Zeichner JA. Inflammatory acne treatment: review of current and new topical therapeutic options. J Drugs Dermatol. 2016;15(1 Suppl 1):s11-s16.
16. Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74:945-73.e33.
17. Hsu P, Litman GI, Brodell RT. Overview of the treatment of acne vulgaris with topical retinoids. Postgrad Med. 2011;123:153-61.
18. Kaplan YC, Ozsarfati J, Etwel F, Nickel C, Nulman I, Koren G. Pregnancy outcomes following first-trimester exposure to topical retinoids: a systematic review and meta-analysis. Br J Dermatol. 2015;173:1132-41.
19. Del Rosso JQ. Clinical relevance of skin barrier changes associated with the use of oral isotretinoin: the importance of barrier repair therapy in patient management. J Drugs Dermatol. 2013;12(6):626-31.
AUTHOR CORRESPONDENCE
Anneke Andriessen PhD anneke.a@tiscali.nl
